About this Research Topic
Although significant advances have been made in the treatment of depressive disorders during the last decades, there are still unmet therapeutic needs in patients diagnosed with this type of pathology. Besides a high rate of non-responsiveness, tolerability challenges have been reported when antidepressants are administered, therefore raising the rate of therapeutic non-adherence. The perseverance of researchers and clinicians dedicated to improving patients’ chances to reach better therapeutic responses and functional remission, led to the launching of a "new wave" of antidepressants.
Agents with different mechanisms of action, such as partial agonism of type 1A serotonergic receptors, glutamatergic modulation, simultaneous inhibition of the three monoamine transporters, allosteric modulation of GABA--A receptors, or a mixture of two pharmacological agents with different pharmacodynamic properties in a single tablet, are expected to enrich the pharmacological armamentarium of clinicians who treat patients with depressive disorders. Gepirone, esketamine, toludesvenlafaxine, zuranolone, brexanolone, and the combination dextromethorphan+bupropion are the representatives of this new generation of antidepressants, all of which have been approved in the last five years by different national or regional agencies with responsibilities in the domain of medicines authorization, for major depressive disorder, postpartum depression, or treatment-resistant depression.
The aim of this Research Topic is to collect new data on the pharmacovigilance of antidepressants representing the new wave of therapeutic solutions for depressive disorders.
Areas covered in this Research Topic may include, but are not limited to:
- Clinical efficacy and tolerability of recently approved antidepressants
- Enriching the spectrum of recommendations for the new generation antidepressants- from major depressive disorder to anxiety disorders, and from sexual dysfunctions to bipolar disorders
- Clinical challenges when using new antidepressants- case reports and case series
- Treatment adherence, tolerability, and quality of life in patients using new-generation antidepressants
- Systematic reviews and meta-analyses exploring the impact of new antidepressants on essential clinical variables
- Original research focused on switching from other agents to new-generation antidepressants- advantages and challenges
- Pharmacogenetic-driven treatment of depressive disorders – new steps toward individualized medicine
Agents with different mechanisms of action, such as partial agonism of type 1A serotonergic receptors, glutamatergic modulation, simultaneous inhibition of the three monoamine transporters, allosteric modulation of GABA--A receptors, or a mixture of two pharmacological agents with different pharmacodynamic properties in a single tablet, are expected to enrich the pharmacological armamentarium of clinicians who treat patients with depressive disorders. Gepirone, esketamine, toludesvenlafaxine, zuranolone, brexanolone, and the combination dextromethorphan+bupropion are the representatives of this new generation of antidepressants, all of which have been approved in the last five years by different national or regional agencies with responsibilities in the domain of medicines authorization, for major depressive disorder, postpartum depression, or treatment-resistant depression.
The aim of this Research Topic is to collect new data on the pharmacovigilance of antidepressants representing the new wave of therapeutic solutions for depressive disorders.
Areas covered in this Research Topic may include, but are not limited to:
- Clinical efficacy and tolerability of recently approved antidepressants
- Enriching the spectrum of recommendations for the new generation antidepressants- from major depressive disorder to anxiety disorders, and from sexual dysfunctions to bipolar disorders
- Clinical challenges when using new antidepressants- case reports and case series
- Treatment adherence, tolerability, and quality of life in patients using new-generation antidepressants
- Systematic reviews and meta-analyses exploring the impact of new antidepressants on essential clinical variables
- Original research focused on switching from other agents to new-generation antidepressants- advantages and challenges
- Pharmacogenetic-driven treatment of depressive disorders – new steps toward individualized medicine
Keywords: gepirone, toludesvenlafaxine, esketamine, zuranolone, brexanolone, dextromethorphan, bupropion, 5HT1A partial agonists, glutamate, GABA-A allosteric modulators
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
